[Mechanisms of yiqi tongluo pill on oxygen free radicals, nitric oxide and fibrinolysis in coronary heart diseases and hypertension patients].
OBJECTIVE
To clarify the mechanism of Yiqi Tongluo Pill (YQTLP) in treating coronary heart disease and hypertension.


METHODS
The clinical effects of YQTLP on 97 coronary heart diseases (CHD) and hypertension patients, in comparing to the 92 patients treated with nitroglycerin was investigated. The changes of plasma lipid peroxide (LPO), superoxide dismutase (SOD), tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) and nitric oxide (NO) were observed in the patients treated with YQTLP and nitroglycerin, which were compared to 30 healthy subjects.


RESULTS
The levels of LPO and PAI increased and the levels of SOD, t-PA and NO decreased significantly in the patients. The clinical effects of YQTLP were better than that of nitroglycerin in the patients with unstable angina, while the effects of YQTLP were worse than that of nitroglycerin in the patients of hypertension and hypertension with CHD. YQTLP could decrease the levels of LPO and PAI and increase the levels of SOD, t-PA and NO significantly. The effects of YQTLP on t-PA and SOD were better than that of nitroglycerin.


CONCLUSIONS
The protective mechanisms of YQTLP were related to inhibit lipid peroxidation, protect endothelium-derived relaxing factor and adjust the fibrinolytic activities.
D000328:Adult; D000368:Aged; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008054:Lipid Peroxides / Q000097:blood; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000097:blood